FDA, CTTI seeking members for new patient engagement collaborative

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/g-stockstudio)
(Image: Getty/g-stockstudio)
The Patient Engagement Collaborative will include 16 patients, caregivers, and patient group representatives who will provide “a collective, all-encompassing patient voice,” says CTTI project manager.

The US Food and Drug Administration (FDA) has tapped the Clinical Trials Transformation Initiative (CTTI)  to support its Patient Engagement Collaborative.

CTTI is a public-private partnership co-founded by Duke University and the FDA with the goal of increasing the quality of clinical trials.

The new collaborative will be an ongoing forum through which the patient community and regulators will discuss communication, transparency, and new ways for patients and the FDA to work together, explained Zachary Hallinan, CTTI project manager.

The FDA is seeking nominations​ to join the Patient Engagement Collaborative through January 29, 2018.

CTTI and the FDA believe that furthering the engagement of patients as valued partners across the research and development continuum requires an open forum for patients and regulators to discuss and exchange ideas​,” Hallinan said.

Creation of the collaborative follows public feedback the FDA requested on Section 1137​, Patient Participation in Medical Product Discussions, of the Food and Drug Administration Safety and Innovation Act (FDASIA).

As part of this feedback, Hallinan explained that it was suggested an outside group be created to provide input on patient engagement.

The goal in creating this collaborative is to bring together members of the patient community to discuss the best ways for patients to participate in the FDA’s regulatory discussions about medical products​,” he added.

Engaging patients as partners in the development of medical products is critical to the success of the clinical research enterprise​.”

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers